The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11111 malaria professionals are enjoying the free benefits of MalariaWorld today

drugs

NOT Open Access | Ototoxic hearing loss from antimalarials: A systematic narrative review

September 8, 2021 - 17:04 -- NOT Open Access
Author(s): 
Dillard LK, Fullerton AM, McMahon CM
Reference: 
Travel Med Infect Dis. 2021 Sep-Oct;43:102117 Background

Drugs used in curative and prophylactic antimalarial treatment may be ototoxic and lead to permanent hearing loss, but there is no consensus regarding prevalence and permanence of ototoxic hearing loss caused by antimalarials. The purpose of this systematic narrative review was to synthesize current evidence on antimalarial ototoxicity in human populations.

Not Open Access | S-Adenosyl-L-homocysteine hydrolase: Its Inhibitory Activity against Plasmodium falciparum and Development of Malaria Drugs

December 23, 2020 - 09:47 -- NOT Open Access
Author(s): 
Chandra G, Patel S, Panchal M, Singh DV
Reference: 
Mini Rev Med Chem. 2020 Dec 18

Parasite Plasmodium falciparum is continuously successful to give a challenge to human beings by changing itself against most of the antimalaria drugs and its consequences can be seen by huge death each year due to malaria especially in the poor and developing country. Due to its ability to drug resistance, new drugs are regularly needed to kill the organism. Many new drugs have been developed based on different mechanisms. One of the potential mechanisms is to hamper protein synthesis by blocking the gene expression. S-Adenosyl-L-homocysteine (SAH) hydrolase is a NAD+ dependent tetrameric enzyme, which is responsible for the reversible hydrolysis of AdoHcy to adenosine and L-homocysteine, has been recognized as a new target for antimalarial agents since the parasite has a specific SAH hydrolase.

NOT Open Access | Malaria transmission-blocking drugs: implications and future perspectives

May 13, 2020 - 13:49 -- NOT Open Access
Author(s): 
Wadi I, Singh P, Nath M, Anvikar AR, Sinha A
Reference: 
Future Med Chem. 2020 May 7

Since the world is inching toward malaria elimination, the scientific community worldwide has begun to realize the importance of malaria transmission-blocking interventions. The onus of breaking the life cycle of the human malaria parasite Plasmodium falciparum predominantly rests upon transmission-blocking drugs because of emerging resistance to commonly used schizonticides and insecticides.

NOT Open Access | Prevalence of mutations in Plasmodium falciparum genes associated with resistance to different antimalarial drugs in Nyando, Kisumu County in Kenya

November 26, 2019 - 13:55 -- NOT Open Access
Author(s): 
Musyoka KB, Kiiru JN, Aluvaala E, Omondi P, Chege WK, Judah T, Kiboi D, Nganga JK, Kimani FT.
Reference: 
Infection, Genetics and Evolution, 19 November 2019, 104121

Resistance to the mainstay antimalarial drugs is a major concern in the control of malaria. Delayed Plasmodium falciparum parasite clearance has been associated with Single Nucleotide Polymorphisms (SNPs) in the kelch propeller region (K13). However, SNPs in the Pf-adaptor protein complex 2 mu subunit (Pfap2-mu), Pfcrt and Pfmdr1 are possible markers associated with multi-drug resistance. Here, we explored the prevalence of SNPs in the K13, Pfap2-mu, Pfcrt, and Pfmdr1 in 94 dried blood spot field isolates collected from children aged below 12 years infected with P. falciparum during a cross-sectional study.

Country: 
Subscribe to RSS - drugs